1. Pink Sheet
  2. >>Pathways & Standards

DREAMM Comeback Prompts GSK To Seek Fast-Track EMA Review For Blenrep

 
• By Neena Brizmohun

The European Medicines Agency is this week deciding whether the planned EU filings for sipavibart, lifileucel and Blenrep – which was previously approved but withdrawn in the EU and the US – merit an accelerated assessment.

fast capsule
The EMA is considering requests to speed up its reviews for three treatments • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

GSK has asked the European Medicines Agency to fast track its planned EU marketing application for belantamab mafodotin, the company’s multiple myeloma treatment that was approved in the EU and the US as Blenrep but then withdrawn from both markets following a confirmatory study failure.

The move follows positive results from two Phase III trials that evaluated the drug in multiple myeloma treatment settings different...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

 
• By Anju Ghangurde

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.